Erythropoietin deficiency in the anaemia of chronic disorders
| Autor: | H. K. Boyd, Terence R.J. Lappin |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Anemia Malignancy Gastroenterology Neoplasms Rheumatic Diseases hemic and lymphatic diseases Internal medicine medicine Humans Erythropoietin Anemia Hypochromic business.industry Hematology General Medicine Middle Aged medicine.disease Haemolysis Chronic disorders Rheumatoid arthritis Chronic Disease Immunology Rheumatoid disease Kidney Failure Chronic Erythropoiesis Female business medicine.drug |
| Zdroj: | European Journal of Haematology. 46:198-201 |
| ISSN: | 1600-0609 0902-4441 |
| DOI: | 10.1111/j.1600-0609.1991.tb00540.x |
| Popis: | Defective iron metabolism, mild haemolysis and impaired erythropoiesis contribute to the anaemia of chronic disorders (ACD), but evidence for a deficiency of circulating erythropoietin (Epo) is equivocal. We have examined serum Epo in moderately anaemic patients with Hb less than 10 g/dl--41 patients with ACD (23 associated with rheumatoid disease and 18 with malignancy), 17 with uncomplicated iron-deficiency anaemia and 33 with chronic renal failure (CRF). In ACD the serum Epo (mean (confidence limits] results of 41 (31, 54) mU/ml for the rheumatoid group and 63 (49, 80) mU/ml for the malignancy group, were significantly lower than the Epo of 104 (78, 136) mU/ml for the iron-deficiency group. The CRF group with more severe anaemia had serum Epo of 27 (19, 35) mU/ml. Thus, recombinant human erythropoietin (rHu Epo) should be considered for the treatment of ACD associated with rheumatoid disease and malignancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text